{"ticker": {"uuid": "6144aba4-b482-47d7-90e0-d33914f45c00", "symbol": "ACHV", "name": "Achieve Life Sciences Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Canaccord reiterates Achieve Life Sciences stock rating on CRL review", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPMGExaUdRZFItZEh5VUJFN0p2c09BZUJ3bHBJM0ZTaW44dVIyek5Rd2dYT3NtX1JTWGI4MjVUWUo1a2Y4QWVRRjZ5aTJjUF83cEplQjRtcFBWdDVrMURVNHVSYUpRS3BzOGcyTEhPcjE5YlBzMTRhOF9nVXowQUxRbVMxVFNNS0V5eU5VM0Q2RmloM2pVcHVYZlZyaDY1ejlGbnY5UkRjUGUzQnZqRHRDajhxVnBPMHlreXM2S1JSejRHSDFNOTZZeA?oc=5", "source_name": "Investing.com", "published_at": "2026-07-14T11:49:05+00:00", "published_display": "14 Jul 2026 11:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Achieve Life Sciences (NASDAQ:ACHV) Trading Down 7.7% - Should You Sell?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOSnFPdGVwVUVfazE5VVVLZHVTTmhYTGJLTWVNVTRwbFpKWEhLekZiWUhySTVHUURNRmxXOUw4cEZfMW5aMHBmSjRzQ012UFVhbnNQVGZnT19HcnpnNm85cU5PY21IYTlBYWZoZnJhcHdVd2tDU1VqLUpiclpvRHBLZk9uT2tnRzZwZnVsVEFIS3pnVmVxbmdwLWo4WUVrdVJYZ0VBcmNhWllQU0tGdUVMY3FCSC1uUzRJX1E?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-10T16:47:52+00:00", "published_display": "10 Jul 2026 16:47", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences Inc. (ACHV) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live quotes and charts for Achieve Life Sciences Inc. (ACHV) stock, showing its current price at $6.40 with no change. It notes that there are no analyst ratings or earnings information currently available for ACHV. The article also includes a general disclaime", "url": "https://timothysykes.com/quote/ACHV/", "source_name": "timothysykes.com", "published_at": "2026-07-10T11:39:36", "published_display": "10 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences Stockholders Weigh Board Slate, Share Increase at Annual Meeting", "summary": "Achieve Life Sciences (NASDAQ: ACHV) held its 2026 annual meeting virtually, where stockholders considered the election of nine directors, ratification of PricewaterhouseCoopers LLP as independent auditor, and a non-binding say-on-pay proposal for executive compensation. The most", "url": "https://finance.yahoo.com/markets/stocks/articles/achieve-life-sciences-stockholders-weigh-000153702.html", "source_name": "Market source", "published_at": "2026-07-09T23:39:36", "published_display": "09 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivo Opportunity group reports 5.0% stake in Achieve Life Sciences | ACHV SEC Filing - Form SCHEDULE 13G", "summary": "Vivo Opportunity Group has reported a 5.0% beneficial ownership stake in Achieve Life Sciences (ACHV) through a SCHEDULE 13G SEC filing. This collective ownership, totaling 5,305,640 shares, includes both currently held common stock and shares issuable upon the exercise of warran", "url": "https://www.stocktitan.net/sec-filings/ACHV/schedule-13g-achieve-life-sciences-inc-passive-investment-disclosure--b1dad0b4faa6.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:40:21", "published_display": "08 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences: Despite CRL, A Success Is Achieve-Able (NASDAQ:ACHV)", "summary": "Achieve Life Sciences (ACHV) has seen significant movement in its stock, including a recent rally, despite a Complete Response Letter (CRL) from the FDA. The author maintains a \"strong buy\" rating, noting that recent financing, supply chain improvements, and new leadership have d", "url": "https://seekingalpha.com/article/4920351-achieve-life-sciences-despite-crl-a-success-is-achieve-able", "source_name": "Seeking Alpha", "published_at": "2026-07-07T11:33:00", "published_display": "07 Jul 2026 11:33", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] ACHIEVE LIFE SCIENCES, INC. Reports Material Event", "summary": "ACHIEVE LIFE SCIENCES, INC. filed an 8-K report detailing the outcomes of its annual meeting of stockholders. Key approvals included increasing authorized common stock from 150,000,000 to 300,000,000 shares, the election of nine directors, and the ratification of PricewaterhouseC", "url": "https://www.stocktitan.net/sec-filings/ACHV/8-k-achieve-life-sciences-inc-reports-material-event-0b831f559194.html", "source_name": "Stock Titan", "published_at": "2026-07-06T19:41:05", "published_display": "06 Jul 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACHV Stock On Track To For Best Day In Over 7 Years \u2014 What\u2019s Driving The Rally?", "summary": "Achieve Life Sciences (ACHV) shares surged 42% after the company appointed a new CEO and announced a private placement of up to $354 million. This move comes as the company prepares for regulatory approval of its experimental nicotine dependence drug, cytisinicline, despite antic", "url": "https://stocktwits.com/news-articles/markets/equity/achv-stock-on-track-for-best-day-in-over-7-years-whats-driving-the-rally/cZJvoz0RIDM", "source_name": "Stocktwits", "published_at": "2026-07-04T10:10:35", "published_display": "04 Jul 2026 10:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACHV - Achieve Life Sciences Inc Latest SEC Filings", "summary": "This article provides a comprehensive overview of Achieve Life Sciences Inc (ACHV), including its latest stock performance data, financial figures, key ratios, and insider/institutional ownership. It details market capitalization, income, sales, per-share values, and various perf", "url": "https://finviz.com/stock?t=ACHV&ta=1&p=m&ty=lf&b=1", "source_name": "Finviz", "published_at": "2026-07-02T21:40:11", "published_display": "02 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences joins Russell 2000 in reconstitution", "summary": "Achieve Life Sciences (Nasdaq: ACHV) has been added to the Russell 2000 Index, effective June 26, 2026, as part of the Russell U.S. Indexes reconstitution. The company, which is developing cytisinicline for nicotine dependence, is also a member of the Russell 3000 Index. This inc", "url": "https://www.stocktitan.net/news/ACHV/achieve-life-sciences-joins-russell-2000-vlkfb764fay8.html", "source_name": "Stock Titan", "published_at": "2026-07-02T01:42:47", "published_display": "02 Jul 2026 01:42", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences (ACHV) Joins Russell 2000 Index", "summary": "Achieve Life Sciences (ACHV) has been included in the Russell 2000 Index, a significant milestone expected to increase its visibility and institutional investment. Despite this, the company has a low GF Score\u2122 of 32/100, moderate financial strength (5/10), and significant profita", "url": "https://www.gurufocus.com/news/8936308/achieve-life-sciences-achv-joins-russell-2000-index", "source_name": "GuruFocus", "published_at": "2026-06-29T14:09:38", "published_display": "29 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences added to Russell 2000 index By Investing.com", "summary": "Achieve Life Sciences (NASDAQ:ACHV) has been added to the Russell 2000 Index, reflecting strong investor interest with a 170% return over the past year. The pharmaceutical company is focused on developing cytisinicline for nicotine dependence treatment and is also a member of the", "url": "https://m.za.investing.com/news/stock-market-news/achieve-life-sciences-added-to-russell-2000-index-93CH-4347895?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-29T13:09:38", "published_display": "29 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences Joins Russell 2000\u00ae Index", "summary": "Achieve Life Sciences, a specialty pharmaceutical company focused on treating nicotine dependence with cytisinicline, announced its inclusion in the Russell 2000\u00ae Index, effective June 26, 2026. The company is also part of the Russell 3000\u00ae Index, significant benchmarks for insti", "url": "https://www.globenewswire.com/news-release/2026/06/29/3318944/0/en/achieve-life-sciences-joins-russell-2000-index.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T12:09:38", "published_display": "29 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Achieve Life Sciences, Inc. \u2013 NASDAQ:ACHV", "summary": "This article provides financial information for Achieve Life Sciences, Inc. (NASDAQ: ACHV), specifically focusing on its Price to Earnings (forward) metric. It is hosted on TradingView, a financial platform offering various market tools and data.", "url": "https://www.tradingview.com/symbols/NASDAQ-ACHV/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T08:10:43", "published_display": "29 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Achieve Life Sciences, Inc. \u2013 NASDAQ:ACHV", "summary": "This article focuses on the enterprise value to EBITDA forward for Achieve Life Sciences, Inc. (NASDAQ: ACHV). It provides a financial metric for the company as part of a larger financial data overview on TradingView, indicating that specific value details are available through t", "url": "https://www.tradingview.com/symbols/NASDAQ-ACHV/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T16:39:56", "published_display": "28 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences, Inc. Actuals & Estimates (NASDAQ:ACHV)", "summary": "This article provides an overview of Achieve Life Sciences, Inc. (NASDAQ: ACHV) stock performance, financial estimates, and analyst forecasts. It covers the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings reports, along wit", "url": "https://www.tradingview.com/symbols/NASDAQ-ACHV/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:39:41", "published_display": "26 Jun 2026 09:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canaccord reiterates Achieve Life Sciences stock rating after CRL", "summary": "Canaccord Genuity reiterated a Buy rating and a $13.00 price target for Achieve Life Sciences (NASDAQ:ACHV) after the company received a Complete Response Letter (CRL) from the FDA for cytisinicline. The CRL was due to manufacturing issues at a third-party facility and incomplete", "url": "https://www.investing.com/news/analyst-ratings/canaccord-reiterates-achieve-life-sciences-stock-rating-after-crl-93CH-4755469", "source_name": "Investing.com", "published_at": "2026-06-23T13:11:18", "published_display": "23 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 60, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wainwright reiterates Achieve Life Sciences stock rating after FDA letter", "summary": "H.C. Wainwright maintained a Buy rating and $12.00 price target for Achieve Life Sciences (NASDAQ:ACHV) despite the company receiving a Complete Response Letter from the FDA for its cytisinicline drug. The FDA's concerns were related to manufacturing and labeling, not clinical ef", "url": "https://www.investing.com/news/analyst-ratings/wainwright-reiterates-achieve-life-sciences-stock-rating-after-fda-letter-93CH-4755273", "source_name": "Investing.com", "published_at": "2026-06-23T12:09:59", "published_display": "23 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences: Their CRL Is Fixable, So I Remain Bullish (NASDAQ:ACHV)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPaWdUNFhQTTNHUmU0Q2VTcC1BR29LZ3E2S2M4bnFxMmtIZWxJdGs2RERlZnhfMUlKVm9ZaXBUVjF0XzhCZzdLT0hMSUEzcEg3SldMNXU4eVZ6VkhTalRrV2lpWWoyem9yT3MzUFh2MkxzRm1xZy1HS0pBbmYzWUxjeWREWDA4WUhnY2Y3OURSNkNSYlE3MUZkSnBhcnU0VUVEY3c?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences stock falls after FDA issues response letter", "summary": "Achieve Life Sciences' stock fell after the FDA issued a Complete Response Letter for its New Drug Application for cytisinicline, a nicotine dependence treatment. The letter cited deficiencies at a third-party manufacturing facility and incomplete product labeling, but not issues", "url": "https://www.investing.com/news/stock-market-news/achieve-life-sciences-stock-falls-after-fda-issues-response-letter-93CH-4752699", "source_name": "Investing.com", "published_at": "2026-06-23T05:40:58", "published_display": "23 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences (NasdaqCM:ACHV) Stock Forecast & Analyst Predictions", "summary": "Achieve Life Sciences (ACHV) is forecast to grow earnings and revenue significantly, with analysts expecting profitability within the next three years, despite some recent setbacks regarding its cytisinicline NDA. The FDA issued a Complete Response Letter for cytisinicline due to", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-achv/achieve-life-sciences/future", "source_name": "Simply Wall Street", "published_at": "2026-06-22T18:10:45", "published_display": "22 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences Receives FDA Complete Response Letter for Cytisinicline", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/achieve-life-sciences-receives-fda-144057317.html", "source_name": "MT Newswires", "published_at": "2026-06-22T14:40:57+00:00", "published_display": "22 Jun 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA declines to approve Achieve Life Sciences' smoking-cessation drug", "summary": "The FDA has declined to approve Achieve Life Sciences' smoking-cessation drug, cytisinicline, due to issues at a third-party manufacturing facility and incomplete product labeling. The company plans to resubmit its application in Q4 2026, with potential FDA approval in the first ", "url": "https://www.reuters.com/legal/litigation/us-fda-declines-approve-achieve-life-sciences-smoking-cessation-drug-2026-06-22/", "source_name": "Reuters", "published_at": "2026-06-22T12:54:00", "published_display": "22 Jun 2026 12:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA", "summary": "Achieve Life Sciences received a Complete Response Letter (CRL) from the FDA for its cytisinicline New Drug Application due to manufacturing deficiencies at a third-party facility and uncompleted final product labeling. The FDA identified no issues with the drug's efficacy or cli", "url": "https://www.globenewswire.com/news-release/2026/06/22/3315277/0/en/achieve-life-sciences-receives-complete-response-letter-from-fda-for-cytisinicline-nda.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T12:41:47", "published_display": "22 Jun 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences receives FDA rejection on manufacturing issues", "summary": "Achieve Life Sciences Inc. received a Complete Response Letter from the FDA regarding its New Drug Application for cytisinicline, citing manufacturing issues at a third-party facility and incomplete product labeling, rather than concerns about the drug's clinical efficacy or safe", "url": "https://www.investing.com/news/company-news/achieve-life-sciences-receives-fda-rejection-on-manufacturing-issues-93CH-4752716", "source_name": "Investing.com", "published_at": "2026-06-22T12:39:57", "published_display": "22 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life FDA rejects cytisinicline filing over manufacturing issues", "summary": "Achieve Life Sciences (Nasdaq: ACHV) received a Complete Response Letter (CRL) from the FDA for its cytisinicline NDA due to manufacturing deficiencies at a prior third-party facility and incomplete product labeling. The FDA did not identify any issues with the clinical efficacy ", "url": "https://www.stocktitan.net/news/ACHV/achieve-life-sciences-receives-complete-response-letter-from-fda-for-bq6u8i3hos6m.html", "source_name": "Stock Titan", "published_at": "2026-06-22T12:39:57", "published_display": "22 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences Inc (ACHV) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Achieve Life Sciences Inc (ACHV) has an earnings forecast score of 8.00, placing it 165th among 389 companies in the Biotechnology & Medical Research industry. Analysts maintain a \"Buy\" rating for ACHV, with an average price target of $14.00, suggesting a significant upside. The ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-achv/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T04:09:07", "published_display": "18 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences Inc (ACHV) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Achieve Life Sciences Inc (ACHV), highlighting its current price momentum, support and resistance levels, and signals from various technical indicators and moving averages. While the stock shows a current price momentum score of 8.96 ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-achv/technical", "source_name": "TradingKey", "published_at": "2026-06-17T05:39:31", "published_display": "17 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[ARS] ACHIEVE LIFE SCIENCES, INC. SEC Filing", "summary": "This article announces an SEC filing of Form ARS by ACHIEVE LIFE SCIENCES, INC. (ACHV) on June 8, 2026, at 04:07 PM. The filing has a low impact and neutral sentiment. The article provides an overview of ACHV's stock performance, recent news, and other SEC filings.", "url": "https://www.stocktitan.net/sec-filings/ACHV/ars-achieve-life-sciences-inc-sec-filing-3fc96c6ab600.html", "source_name": "Stock Titan", "published_at": "2026-06-09T00:39:28", "published_display": "09 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors", "summary": "Achieve Life Sciences has appointed Jeffrey Farrow and Reid Waldman, MD to its Board of Directors to bolster the company's commercial strategy, clinical, and finance expertise. These appointments come as Achieve prepares for the potential approval and launch of cytisinicline, a t", "url": "https://www.globenewswire.com/news-release/2026/06/02/3305161/0/en/Achieve-Life-Sciences-Appoints-Jeffrey-Farrow-and-Reid-Waldman-MD-to-Board-of-Directors.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T09:09:49", "published_display": "03 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACHIEVE Life Sciences (ACHV) director reports no beneficial ownership on Form 3", "summary": "ACHIEVE Life Sciences, Inc. director Reid Alexander Waldman filed an initial Form 3, indicating no beneficial ownership of the company's securities with 0 shares held directly. This filing establishes his baseline holdings as he becomes a reporting insider, offering transparency ", "url": "https://www.stocktitan.net/sec-filings/ACHV/form-3-achieve-life-sciences-inc-initial-statement-of-beneficial-owne-287300da2f9f.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:18:55", "published_display": "02 Jun 2026 20:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two biotech leaders join Achieve Life's new quitting drug push", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOYk5ObHRCa0k1WUNwT0lsY0pCaTc4UlZmWHNRNE45LVhRUEVFWWl3QktUaVdxU0hGSWdjVFNtR2Q2NnFQUGtQWENEUzBYaFdDaTlsZTVYOG9VU0dTNHR0TzlieVRHWm13QUkzZm1LT1Bab1RIcWNScU9fYXlHNEthLVJ1LWlPZFNSSUhNdWdVZHdTMDVPc2ZJV3ZOQ0kxZjhkd2dwUm9zWHFBSVlZOWJZMFpuV2V0OFh0STRIaWR2OTM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/achieve-life-sciences-presents-safety-181500734.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T18:15:00+00:00", "published_display": "19 May 2026 18:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Achieve Life Sciences Inc (ACHV) Q1 2026 Earnings Call Highlights: Strategic Financing and ...", "summary": "", "url": "https://finance.yahoo.com/news/achieve-life-sciences-inc-achv-230431050.html", "source_name": "GuruFocus.com", "published_at": "2026-05-12T23:04:31+00:00", "published_display": "12 May 2026 23:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/df260348-b019-3bea-b90a-d6448d9d95d5/achieve-life-sciences%2C-inc..html", "source_name": "Moby", "published_at": "2026-05-12T16:55:39+00:00", "published_display": "12 May 2026 16:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/dab512b0-d8b2-3b16-b9bb-e8661bc2a880/achieve-life-sciences-q1.html", "source_name": "MarketBeat", "published_at": "2026-05-12T14:08:50+00:00", "published_display": "12 May 2026 14:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxNUHlsa0dqOEFSWVVxaUhPRmphS3JSc0dJbGYzaDVTR0hUY2o0czExZVhWRnczWGlwYkY2S1REdG9DU0gxTEhoUXcwcVVCMU5TbXhnbDQ4dzE0SE1RVDJqMUZ4a1hyVVgxZjNPZHUyWEg3STNyenJ6ZmkwNEtXYTJsVEstM2QxR3Y2YXp6TkpDTENLczJ3X3ZwWE1rS3dpbFJYb0N5bDRyWXN4amNacmxuZVJnWWJsY2VCczI4ako0LUpBODhIcTFoU1VPemh0bXdhRVdhdXZJeWQ1cncwLUQzc2FiYVIwSmdMaUM1c0paMTBteGZ4WXlPdWRCUk8?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verona launch team joins Achieve Life\u2019s bid to launch smoking therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQd0hzSWhQSTNWZkxFbnBQemV6OExocTBKZ0xiZzNIX3hsMVU0eG1ZOEJQOXY3N2NwcUsxZ1ZDYlB1c0U4R2gtaXZtUURlM2h6N09DOWVnaF9scWRzZGNVUHM5bzhRRGJkTlBmaHRRRFNITkR1VUk3RUlxcHF0cTZFc2J2UWpkN1o3MnNmYnZYRFBxYVRfUkhWV2JUaFZ5VTdjTzJyNHFjbUo0OXZQSDRZVU80YWFvdGxOUEhlTg?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors commit $354M to Achieve Life's potential new stop-smoking drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQbEpXbVdpQlI1LWk5dDFaOFhaajh3bnNiVldUUFlpV3h0SkxhWFZBb2p6SVdOY2QzWUlLdlZJSU04TUpPY1BnbU5SbEhlVWd6aUR0UGt1S0JBYktvbDRpZmNWVmVFOUl6QzZfdnBXSFhMa1VuLTZ1bVBfdTdWZkJIQmY2UXdjZ09WU3VjWWFCc0tMa3E3T2tBVjhKT0g5RUVqYm9LQUZ3S1RHZ0djdkl0YlhwRXVKYWNsaTlkSjlB?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Achieve Life will post quarterly results before a May 12 webcast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPNHdvY0dfTUxvbl9mVE9RY0J1VDdmb29YM091SnJUY0Z0MkZxekhaOFBySjV2cDh6Q1J6U2tjVmlvTkd6dVdDZFh0VW5yZEFqTllmY3FkUXE2aHhSLV93Y2N5OEZ2TGUyTnY0ai1Fc0xvb1dBZ2w0ZTNKY3NYVE9mZ3ZMaFNzeU5mQmRMYWsyNDR2enBXdUk5XzVWVTFiSUQ2Rld4Z0d3eXhvd2psVEdpY0EwWmwxclJV?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Achieve Life Sciences (ACHV) grants CEO large PRSU, option and RSU awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPclcxUUVJY19rU1huS2VNZHBOVkZleE91Y1JmVWp0TVlES1hOVElaWDlJdzVxcWRXbFRqX2J3TzNxaU81cVhTdzB1dkhVZDFHSTBaUlM0SU51T1U1cmZFcjRJX2xZZktnWFhYRnM1OWs3NW9ETERSQW9ZTlpDQ1F3bGFMSV90MVIxbFlSbmlkdC1neVFvaW8teWhYRjV2WWJKTWpSazRsU3R1bU1rc2k1b3ZLdjloQ2E5Ull3?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Achieve Life Sciences Secures $354 Million Financing to Advance Cytisinicline Development for Nicotine Dependence", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxNcUMxdlVIdG5RVjFxRkdlS1dwT3ZFSS15ZWxva1NQVnZQQ0V3VFBBYXoxeGQ4R0I0eDdsb3dzb2VGZ1haMEg4WTdaNWdBWEJxNmtpNkdmQ3JuUVhMXzBNSjl0M2pKT0kxeHNUQVBQUXkzX1FXSWlPcklLeWVaSWs4bm04RVJfWVcyNV9UdnRMeW1xbEljTnFPcHlZblBab29aSUlNYzd5dlNiemYzbjNxTXFNNGNuVzBiSThZRU9PMlk0VWxZRS0tQlZmaENmRzFJZnVBcFl3Q1hxYVlHYnhV?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve secures $180M now, with $174M more tied to FDA approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPbVZSelJ3RXFGeGJsS3BVS2xmcjNCT3JDUXpqZHc3UXY2U0dGQzR2Z3AtQU90alZsRi1fNDI1QnFkX0loVGFsZE9YeEVVYktBUEp4ZVMxVTl2eDdRYmd5d3dCaXh4Smdhb19WOTctZWwzQ1FYalRKc1pUQVpCcE9reTJxY25WdXd0Rmx0M3pOTV9nRW9SUjR5VHJmaTVNSDVlVTJXVDZPTHhQSUQ4LUtOLThB?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOVV9xMjc4Yks1Ql83NFJjN2lkUmtYZVJMZi1JUDBfN19QT0ZJWW9DcTdEcnVvdEhHSDF6YjIxSDBNdFFRT2tGYTV3cjhlekQ2clFyekZtQ2FXUmcxcDh1XzBUVkM3eXpQN0diSGZjRUJtclVmdDlub21lbjZmYUttYTBwY0wxeWVIak5hdmY3MlBvQTE3eWpteXlncmkwRmNQZ0Z3T3I1alBmazZBWmVfb21B?oc=5", "source_name": "Market source", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOVUJoN1dJWWtOeXFzREk5aDAwYkd3cUJaZFFJNktzZVV3UmFnWkctRU0tUEIybkFNc3dyWUVWWlZON083NGR6T2o0TnFkaFpGZEVnaGYyYTk1YTlQVmZ3RHB1WHMza21FQ24xNXpUblhNVWltSDFaM0VSN2hPMUMxTU5uWk9QTlRma3gyWU5iNnZ4Ymsxd1M3ZnRRb2xRSjlLLVY4ZGZJZUk?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences, Inc. (ACHV): A Bull Case Theory", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNUmh5ZVJQX0d6U1JWSDc1UEhOYWFSdDdEY0lSejc3WHpYWWI0bDNqT2pkOGVZYXM4N05fTmhYblF1YXpxUWdrc0FHSTFvUGs5clpEY1RmRkVLenBoeHZINTRhN1JFQXVwbGMwc3F1N05nRXJoZWpzUFV6cFhiR3VaYldn?oc=5", "source_name": "Market source", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Canaccord reiterates Achieve Life Sciences stock rating on CRL review", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPMGExaUdRZFItZEh5VUJFN0p2c09BZUJ3bHBJM0ZTaW44dVIyek5Rd2dYT3NtX1JTWGI4MjVUWUo1a2Y4QWVRRjZ5aTJjUF83cEplQjRtcFBWdDVrMURVNHVSYUpRS3BzOGcyTEhPcjE5YlBzMTRhOF9nVXowQUxRbVMxVFNNS0V5eU5VM0Q2RmloM2pVcHVYZlZyaDY1ejlGbnY5UkRjUGUzQnZqRHRDajhxVnBPMHlreXM2S1JSejRHSDFNOTZZeA?oc=5", "source_name": "Investing.com", "published_at": "2026-07-14T11:49:05+00:00", "published_display": "14 Jul 2026 11:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences (NASDAQ:ACHV) Trading Down 7.7% - Should You Sell?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOSnFPdGVwVUVfazE5VVVLZHVTTmhYTGJLTWVNVTRwbFpKWEhLekZiWUhySTVHUURNRmxXOUw4cEZfMW5aMHBmSjRzQ012UFVhbnNQVGZnT19HcnpnNm85cU5PY21IYTlBYWZoZnJhcHdVd2tDU1VqLUpiclpvRHBLZk9uT2tnRzZwZnVsVEFIS3pnVmVxbmdwLWo4WUVrdVJYZ0VBcmNhWllQU0tGdUVMY3FCSC1uUzRJX1E?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-10T16:47:52+00:00", "published_display": "10 Jul 2026 16:47", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences Inc. (ACHV) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live quotes and charts for Achieve Life Sciences Inc. (ACHV) stock, showing its current price at $6.40 with no change. It notes that there are no analyst ratings or earnings information currently available for ACHV. The article also includes a general disclaime", "url": "https://timothysykes.com/quote/ACHV/", "source_name": "timothysykes.com", "published_at": "2026-07-10T11:39:36", "published_display": "10 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences Stockholders Weigh Board Slate, Share Increase at Annual Meeting", "summary": "Achieve Life Sciences (NASDAQ: ACHV) held its 2026 annual meeting virtually, where stockholders considered the election of nine directors, ratification of PricewaterhouseCoopers LLP as independent auditor, and a non-binding say-on-pay proposal for executive compensation. The most", "url": "https://finance.yahoo.com/markets/stocks/articles/achieve-life-sciences-stockholders-weigh-000153702.html", "source_name": "Market source", "published_at": "2026-07-09T23:39:36", "published_display": "09 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivo Opportunity group reports 5.0% stake in Achieve Life Sciences | ACHV SEC Filing - Form SCHEDULE 13G", "summary": "Vivo Opportunity Group has reported a 5.0% beneficial ownership stake in Achieve Life Sciences (ACHV) through a SCHEDULE 13G SEC filing. This collective ownership, totaling 5,305,640 shares, includes both currently held common stock and shares issuable upon the exercise of warran", "url": "https://www.stocktitan.net/sec-filings/ACHV/schedule-13g-achieve-life-sciences-inc-passive-investment-disclosure--b1dad0b4faa6.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:40:21", "published_display": "08 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences: Despite CRL, A Success Is Achieve-Able (NASDAQ:ACHV)", "summary": "Achieve Life Sciences (ACHV) has seen significant movement in its stock, including a recent rally, despite a Complete Response Letter (CRL) from the FDA. The author maintains a \"strong buy\" rating, noting that recent financing, supply chain improvements, and new leadership have d", "url": "https://seekingalpha.com/article/4920351-achieve-life-sciences-despite-crl-a-success-is-achieve-able", "source_name": "Seeking Alpha", "published_at": "2026-07-07T11:33:00", "published_display": "07 Jul 2026 11:33", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] ACHIEVE LIFE SCIENCES, INC. Reports Material Event", "summary": "ACHIEVE LIFE SCIENCES, INC. filed an 8-K report detailing the outcomes of its annual meeting of stockholders. Key approvals included increasing authorized common stock from 150,000,000 to 300,000,000 shares, the election of nine directors, and the ratification of PricewaterhouseC", "url": "https://www.stocktitan.net/sec-filings/ACHV/8-k-achieve-life-sciences-inc-reports-material-event-0b831f559194.html", "source_name": "Stock Titan", "published_at": "2026-07-06T19:41:05", "published_display": "06 Jul 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACHV Stock On Track To For Best Day In Over 7 Years \u2014 What\u2019s Driving The Rally?", "summary": "Achieve Life Sciences (ACHV) shares surged 42% after the company appointed a new CEO and announced a private placement of up to $354 million. This move comes as the company prepares for regulatory approval of its experimental nicotine dependence drug, cytisinicline, despite antic", "url": "https://stocktwits.com/news-articles/markets/equity/achv-stock-on-track-for-best-day-in-over-7-years-whats-driving-the-rally/cZJvoz0RIDM", "source_name": "Stocktwits", "published_at": "2026-07-04T10:10:35", "published_display": "04 Jul 2026 10:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACHV - Achieve Life Sciences Inc Latest SEC Filings", "summary": "This article provides a comprehensive overview of Achieve Life Sciences Inc (ACHV), including its latest stock performance data, financial figures, key ratios, and insider/institutional ownership. It details market capitalization, income, sales, per-share values, and various perf", "url": "https://finviz.com/stock?t=ACHV&ta=1&p=m&ty=lf&b=1", "source_name": "Finviz", "published_at": "2026-07-02T21:40:11", "published_display": "02 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences joins Russell 2000 in reconstitution", "summary": "Achieve Life Sciences (Nasdaq: ACHV) has been added to the Russell 2000 Index, effective June 26, 2026, as part of the Russell U.S. Indexes reconstitution. The company, which is developing cytisinicline for nicotine dependence, is also a member of the Russell 3000 Index. This inc", "url": "https://www.stocktitan.net/news/ACHV/achieve-life-sciences-joins-russell-2000-vlkfb764fay8.html", "source_name": "Stock Titan", "published_at": "2026-07-02T01:42:47", "published_display": "02 Jul 2026 01:42", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences (ACHV) Joins Russell 2000 Index", "summary": "Achieve Life Sciences (ACHV) has been included in the Russell 2000 Index, a significant milestone expected to increase its visibility and institutional investment. Despite this, the company has a low GF Score\u2122 of 32/100, moderate financial strength (5/10), and significant profita", "url": "https://www.gurufocus.com/news/8936308/achieve-life-sciences-achv-joins-russell-2000-index", "source_name": "GuruFocus", "published_at": "2026-06-29T14:09:38", "published_display": "29 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences added to Russell 2000 index By Investing.com", "summary": "Achieve Life Sciences (NASDAQ:ACHV) has been added to the Russell 2000 Index, reflecting strong investor interest with a 170% return over the past year. The pharmaceutical company is focused on developing cytisinicline for nicotine dependence treatment and is also a member of the", "url": "https://m.za.investing.com/news/stock-market-news/achieve-life-sciences-added-to-russell-2000-index-93CH-4347895?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-29T13:09:38", "published_display": "29 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences Joins Russell 2000\u00ae Index", "summary": "Achieve Life Sciences, a specialty pharmaceutical company focused on treating nicotine dependence with cytisinicline, announced its inclusion in the Russell 2000\u00ae Index, effective June 26, 2026. The company is also part of the Russell 3000\u00ae Index, significant benchmarks for insti", "url": "https://www.globenewswire.com/news-release/2026/06/29/3318944/0/en/achieve-life-sciences-joins-russell-2000-index.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T12:09:38", "published_display": "29 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Achieve Life Sciences, Inc. \u2013 NASDAQ:ACHV", "summary": "This article provides financial information for Achieve Life Sciences, Inc. (NASDAQ: ACHV), specifically focusing on its Price to Earnings (forward) metric. It is hosted on TradingView, a financial platform offering various market tools and data.", "url": "https://www.tradingview.com/symbols/NASDAQ-ACHV/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T08:10:43", "published_display": "29 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Achieve Life Sciences, Inc. \u2013 NASDAQ:ACHV", "summary": "This article focuses on the enterprise value to EBITDA forward for Achieve Life Sciences, Inc. (NASDAQ: ACHV). It provides a financial metric for the company as part of a larger financial data overview on TradingView, indicating that specific value details are available through t", "url": "https://www.tradingview.com/symbols/NASDAQ-ACHV/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T16:39:56", "published_display": "28 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences, Inc. Actuals & Estimates (NASDAQ:ACHV)", "summary": "This article provides an overview of Achieve Life Sciences, Inc. (NASDAQ: ACHV) stock performance, financial estimates, and analyst forecasts. It covers the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings reports, along wit", "url": "https://www.tradingview.com/symbols/NASDAQ-ACHV/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:39:41", "published_display": "26 Jun 2026 09:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canaccord reiterates Achieve Life Sciences stock rating after CRL", "summary": "Canaccord Genuity reiterated a Buy rating and a $13.00 price target for Achieve Life Sciences (NASDAQ:ACHV) after the company received a Complete Response Letter (CRL) from the FDA for cytisinicline. The CRL was due to manufacturing issues at a third-party facility and incomplete", "url": "https://www.investing.com/news/analyst-ratings/canaccord-reiterates-achieve-life-sciences-stock-rating-after-crl-93CH-4755469", "source_name": "Investing.com", "published_at": "2026-06-23T13:11:18", "published_display": "23 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 60, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wainwright reiterates Achieve Life Sciences stock rating after FDA letter", "summary": "H.C. Wainwright maintained a Buy rating and $12.00 price target for Achieve Life Sciences (NASDAQ:ACHV) despite the company receiving a Complete Response Letter from the FDA for its cytisinicline drug. The FDA's concerns were related to manufacturing and labeling, not clinical ef", "url": "https://www.investing.com/news/analyst-ratings/wainwright-reiterates-achieve-life-sciences-stock-rating-after-fda-letter-93CH-4755273", "source_name": "Investing.com", "published_at": "2026-06-23T12:09:59", "published_display": "23 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences: Their CRL Is Fixable, So I Remain Bullish (NASDAQ:ACHV)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPaWdUNFhQTTNHUmU0Q2VTcC1BR29LZ3E2S2M4bnFxMmtIZWxJdGs2RERlZnhfMUlKVm9ZaXBUVjF0XzhCZzdLT0hMSUEzcEg3SldMNXU4eVZ6VkhTalRrV2lpWWoyem9yT3MzUFh2MkxzRm1xZy1HS0pBbmYzWUxjeWREWDA4WUhnY2Y3OURSNkNSYlE3MUZkSnBhcnU0VUVEY3c?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences stock falls after FDA issues response letter", "summary": "Achieve Life Sciences' stock fell after the FDA issued a Complete Response Letter for its New Drug Application for cytisinicline, a nicotine dependence treatment. The letter cited deficiencies at a third-party manufacturing facility and incomplete product labeling, but not issues", "url": "https://www.investing.com/news/stock-market-news/achieve-life-sciences-stock-falls-after-fda-issues-response-letter-93CH-4752699", "source_name": "Investing.com", "published_at": "2026-06-23T05:40:58", "published_display": "23 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences (NasdaqCM:ACHV) Stock Forecast & Analyst Predictions", "summary": "Achieve Life Sciences (ACHV) is forecast to grow earnings and revenue significantly, with analysts expecting profitability within the next three years, despite some recent setbacks regarding its cytisinicline NDA. The FDA issued a Complete Response Letter for cytisinicline due to", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-achv/achieve-life-sciences/future", "source_name": "Simply Wall Street", "published_at": "2026-06-22T18:10:45", "published_display": "22 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences Receives FDA Complete Response Letter for Cytisinicline", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/achieve-life-sciences-receives-fda-144057317.html", "source_name": "MT Newswires", "published_at": "2026-06-22T14:40:57+00:00", "published_display": "22 Jun 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA declines to approve Achieve Life Sciences' smoking-cessation drug", "summary": "The FDA has declined to approve Achieve Life Sciences' smoking-cessation drug, cytisinicline, due to issues at a third-party manufacturing facility and incomplete product labeling. The company plans to resubmit its application in Q4 2026, with potential FDA approval in the first ", "url": "https://www.reuters.com/legal/litigation/us-fda-declines-approve-achieve-life-sciences-smoking-cessation-drug-2026-06-22/", "source_name": "Reuters", "published_at": "2026-06-22T12:54:00", "published_display": "22 Jun 2026 12:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA", "summary": "Achieve Life Sciences received a Complete Response Letter (CRL) from the FDA for its cytisinicline New Drug Application due to manufacturing deficiencies at a third-party facility and uncompleted final product labeling. The FDA identified no issues with the drug's efficacy or cli", "url": "https://www.globenewswire.com/news-release/2026/06/22/3315277/0/en/achieve-life-sciences-receives-complete-response-letter-from-fda-for-cytisinicline-nda.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T12:41:47", "published_display": "22 Jun 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences receives FDA rejection on manufacturing issues", "summary": "Achieve Life Sciences Inc. received a Complete Response Letter from the FDA regarding its New Drug Application for cytisinicline, citing manufacturing issues at a third-party facility and incomplete product labeling, rather than concerns about the drug's clinical efficacy or safe", "url": "https://www.investing.com/news/company-news/achieve-life-sciences-receives-fda-rejection-on-manufacturing-issues-93CH-4752716", "source_name": "Investing.com", "published_at": "2026-06-22T12:39:57", "published_display": "22 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life FDA rejects cytisinicline filing over manufacturing issues", "summary": "Achieve Life Sciences (Nasdaq: ACHV) received a Complete Response Letter (CRL) from the FDA for its cytisinicline NDA due to manufacturing deficiencies at a prior third-party facility and incomplete product labeling. The FDA did not identify any issues with the clinical efficacy ", "url": "https://www.stocktitan.net/news/ACHV/achieve-life-sciences-receives-complete-response-letter-from-fda-for-bq6u8i3hos6m.html", "source_name": "Stock Titan", "published_at": "2026-06-22T12:39:57", "published_display": "22 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences Inc (ACHV) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Achieve Life Sciences Inc (ACHV) has an earnings forecast score of 8.00, placing it 165th among 389 companies in the Biotechnology & Medical Research industry. Analysts maintain a \"Buy\" rating for ACHV, with an average price target of $14.00, suggesting a significant upside. The ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-achv/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T04:09:07", "published_display": "18 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences Inc (ACHV) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Achieve Life Sciences Inc (ACHV), highlighting its current price momentum, support and resistance levels, and signals from various technical indicators and moving averages. While the stock shows a current price momentum score of 8.96 ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-achv/technical", "source_name": "TradingKey", "published_at": "2026-06-17T05:39:31", "published_display": "17 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[ARS] ACHIEVE LIFE SCIENCES, INC. SEC Filing", "summary": "This article announces an SEC filing of Form ARS by ACHIEVE LIFE SCIENCES, INC. (ACHV) on June 8, 2026, at 04:07 PM. The filing has a low impact and neutral sentiment. The article provides an overview of ACHV's stock performance, recent news, and other SEC filings.", "url": "https://www.stocktitan.net/sec-filings/ACHV/ars-achieve-life-sciences-inc-sec-filing-3fc96c6ab600.html", "source_name": "Stock Titan", "published_at": "2026-06-09T00:39:28", "published_display": "09 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors", "summary": "Achieve Life Sciences has appointed Jeffrey Farrow and Reid Waldman, MD to its Board of Directors to bolster the company's commercial strategy, clinical, and finance expertise. These appointments come as Achieve prepares for the potential approval and launch of cytisinicline, a t", "url": "https://www.globenewswire.com/news-release/2026/06/02/3305161/0/en/Achieve-Life-Sciences-Appoints-Jeffrey-Farrow-and-Reid-Waldman-MD-to-Board-of-Directors.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T09:09:49", "published_display": "03 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACHIEVE Life Sciences (ACHV) director reports no beneficial ownership on Form 3", "summary": "ACHIEVE Life Sciences, Inc. director Reid Alexander Waldman filed an initial Form 3, indicating no beneficial ownership of the company's securities with 0 shares held directly. This filing establishes his baseline holdings as he becomes a reporting insider, offering transparency ", "url": "https://www.stocktitan.net/sec-filings/ACHV/form-3-achieve-life-sciences-inc-initial-statement-of-beneficial-owne-287300da2f9f.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:18:55", "published_display": "02 Jun 2026 20:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two biotech leaders join Achieve Life's new quitting drug push", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOYk5ObHRCa0k1WUNwT0lsY0pCaTc4UlZmWHNRNE45LVhRUEVFWWl3QktUaVdxU0hGSWdjVFNtR2Q2NnFQUGtQWENEUzBYaFdDaTlsZTVYOG9VU0dTNHR0TzlieVRHWm13QUkzZm1LT1Bab1RIcWNScU9fYXlHNEthLVJ1LWlPZFNSSUhNdWdVZHdTMDVPc2ZJV3ZOQ0kxZjhkd2dwUm9zWHFBSVlZOWJZMFpuV2V0OFh0STRIaWR2OTM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/achieve-life-sciences-presents-safety-181500734.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T18:15:00+00:00", "published_display": "19 May 2026 18:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences Inc (ACHV) Q1 2026 Earnings Call Highlights: Strategic Financing and ...", "summary": "", "url": "https://finance.yahoo.com/news/achieve-life-sciences-inc-achv-230431050.html", "source_name": "GuruFocus.com", "published_at": "2026-05-12T23:04:31+00:00", "published_display": "12 May 2026 23:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/df260348-b019-3bea-b90a-d6448d9d95d5/achieve-life-sciences%2C-inc..html", "source_name": "Moby", "published_at": "2026-05-12T16:55:39+00:00", "published_display": "12 May 2026 16:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/dab512b0-d8b2-3b16-b9bb-e8661bc2a880/achieve-life-sciences-q1.html", "source_name": "MarketBeat", "published_at": "2026-05-12T14:08:50+00:00", "published_display": "12 May 2026 14:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxNUHlsa0dqOEFSWVVxaUhPRmphS3JSc0dJbGYzaDVTR0hUY2o0czExZVhWRnczWGlwYkY2S1REdG9DU0gxTEhoUXcwcVVCMU5TbXhnbDQ4dzE0SE1RVDJqMUZ4a1hyVVgxZjNPZHUyWEg3STNyenJ6ZmkwNEtXYTJsVEstM2QxR3Y2YXp6TkpDTENLczJ3X3ZwWE1rS3dpbFJYb0N5bDRyWXN4amNacmxuZVJnWWJsY2VCczI4ako0LUpBODhIcTFoU1VPemh0bXdhRVdhdXZJeWQ1cncwLUQzc2FiYVIwSmdMaUM1c0paMTBteGZ4WXlPdWRCUk8?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verona launch team joins Achieve Life\u2019s bid to launch smoking therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQd0hzSWhQSTNWZkxFbnBQemV6OExocTBKZ0xiZzNIX3hsMVU0eG1ZOEJQOXY3N2NwcUsxZ1ZDYlB1c0U4R2gtaXZtUURlM2h6N09DOWVnaF9scWRzZGNVUHM5bzhRRGJkTlBmaHRRRFNITkR1VUk3RUlxcHF0cTZFc2J2UWpkN1o3MnNmYnZYRFBxYVRfUkhWV2JUaFZ5VTdjTzJyNHFjbUo0OXZQSDRZVU80YWFvdGxOUEhlTg?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors commit $354M to Achieve Life's potential new stop-smoking drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQbEpXbVdpQlI1LWk5dDFaOFhaajh3bnNiVldUUFlpV3h0SkxhWFZBb2p6SVdOY2QzWUlLdlZJSU04TUpPY1BnbU5SbEhlVWd6aUR0UGt1S0JBYktvbDRpZmNWVmVFOUl6QzZfdnBXSFhMa1VuLTZ1bVBfdTdWZkJIQmY2UXdjZ09WU3VjWWFCc0tMa3E3T2tBVjhKT0g5RUVqYm9LQUZ3S1RHZ0djdkl0YlhwRXVKYWNsaTlkSjlB?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life will post quarterly results before a May 12 webcast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPNHdvY0dfTUxvbl9mVE9RY0J1VDdmb29YM091SnJUY0Z0MkZxekhaOFBySjV2cDh6Q1J6U2tjVmlvTkd6dVdDZFh0VW5yZEFqTllmY3FkUXE2aHhSLV93Y2N5OEZ2TGUyTnY0ai1Fc0xvb1dBZ2w0ZTNKY3NYVE9mZ3ZMaFNzeU5mQmRMYWsyNDR2enBXdUk5XzVWVTFiSUQ2Rld4Z0d3eXhvd2psVEdpY0EwWmwxclJV?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences (ACHV) grants CEO large PRSU, option and RSU awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPclcxUUVJY19rU1huS2VNZHBOVkZleE91Y1JmVWp0TVlES1hOVElaWDlJdzVxcWRXbFRqX2J3TzNxaU81cVhTdzB1dkhVZDFHSTBaUlM0SU51T1U1cmZFcjRJX2xZZktnWFhYRnM1OWs3NW9ETERSQW9ZTlpDQ1F3bGFMSV90MVIxbFlSbmlkdC1neVFvaW8teWhYRjV2WWJKTWpSazRsU3R1bU1rc2k1b3ZLdjloQ2E5Ull3?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences Secures $354 Million Financing to Advance Cytisinicline Development for Nicotine Dependence", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxNcUMxdlVIdG5RVjFxRkdlS1dwT3ZFSS15ZWxva1NQVnZQQ0V3VFBBYXoxeGQ4R0I0eDdsb3dzb2VGZ1haMEg4WTdaNWdBWEJxNmtpNkdmQ3JuUVhMXzBNSjl0M2pKT0kxeHNUQVBQUXkzX1FXSWlPcklLeWVaSWs4bm04RVJfWVcyNV9UdnRMeW1xbEljTnFPcHlZblBab29aSUlNYzd5dlNiemYzbjNxTXFNNGNuVzBiSThZRU9PMlk0VWxZRS0tQlZmaENmRzFJZnVBcFl3Q1hxYVlHYnhV?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve secures $180M now, with $174M more tied to FDA approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPbVZSelJ3RXFGeGJsS3BVS2xmcjNCT3JDUXpqZHc3UXY2U0dGQzR2Z3AtQU90alZsRi1fNDI1QnFkX0loVGFsZE9YeEVVYktBUEp4ZVMxVTl2eDdRYmd5d3dCaXh4Smdhb19WOTctZWwzQ1FYalRKc1pUQVpCcE9reTJxY25WdXd0Rmx0M3pOTV9nRW9SUjR5VHJmaTVNSDVlVTJXVDZPTHhQSUQ4LUtOLThB?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOVV9xMjc4Yks1Ql83NFJjN2lkUmtYZVJMZi1JUDBfN19QT0ZJWW9DcTdEcnVvdEhHSDF6YjIxSDBNdFFRT2tGYTV3cjhlekQ2clFyekZtQ2FXUmcxcDh1XzBUVkM3eXpQN0diSGZjRUJtclVmdDlub21lbjZmYUttYTBwY0wxeWVIak5hdmY3MlBvQTE3eWpteXlncmkwRmNQZ0Z3T3I1alBmazZBWmVfb21B?oc=5", "source_name": "Market source", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOVUJoN1dJWWtOeXFzREk5aDAwYkd3cUJaZFFJNktzZVV3UmFnWkctRU0tUEIybkFNc3dyWUVWWlZON083NGR6T2o0TnFkaFpGZEVnaGYyYTk1YTlQVmZ3RHB1WHMza21FQ24xNXpUblhNVWltSDFaM0VSN2hPMUMxTU5uWk9QTlRma3gyWU5iNnZ4Ymsxd1M3ZnRRb2xRSjlLLVY4ZGZJZUk?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Achieve Life Sciences, Inc. (ACHV): A Bull Case Theory", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNUmh5ZVJQX0d6U1JWSDc1UEhOYWFSdDdEY0lSejc3WHpYWWI0bDNqT2pkOGVZYXM4N05fTmhYblF1YXpxUWdrc0FHSTFvUGs5clpEY1RmRkVLenBoeHZINTRhN1JFQXVwbGMwc3F1N05nRXJoZWpzUFV6cFhiR3VaYldn?oc=5", "source_name": "Market source", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 90, "total_relevant": 55, "sentiment_summary": {"positive": 13, "negative": 5, "neutral": 37, "score": 54, "total": 55, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 14.65, "count": 26}, {"event": "earnings", "label": "Earnings", "weight": 9.76, "count": 20}, {"event": "analyst", "label": "Analyst action", "weight": 2.55, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.55, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 13, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 6.11, "latest_week": "2026-07-10", "one_week_move": -4.5, "four_week_move": 10.7, "twelve_week_move": 19.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.061966, "market_dynamics_buy_signal": false, "relative_strength": 25.285734, "fair_value_gap": 46.4, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 54.5024, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.5% over one week, +10.7% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 12}, {"label": "Market source", "count": 9}, {"label": "Investing.com", "count": 5}, {"label": "GlobeNewswire", "count": 5}, {"label": "TradingView", "count": 4}, {"label": "MarketBeat", "count": 2}, {"label": "Seeking Alpha", "count": 2}, {"label": "TradingKey", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 46}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 26}, {"label": "Earnings", "count": 20}, {"label": "Analyst action", "count": 4}, {"label": "Regulatory and legal", "count": 4}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "46", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-4.5% over one week, +10.7% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Canaccord reiterates Achieve Life Sciences stock rating on CRL review"}], "updated_at": "2026-07-17T08:05:36.332793+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}